BioneXt LAB Information

CoVive is a CE-certified support and monitoring app (class 1 medical device) developed in response to the SARS-CoV-2 (COVID-19) pandemic.

CoVive provides you with clear information on your state of health, while at the same time offering you self-assessment and self-monitoring functions, as well as explanations of your test results. The app acts as a reassuring companion, a source of reliable information guiding you in all decisions regarding your health.

Just answer a few questions and the CoVive app 

● will issue a recommendation on the need to seek medical assistance in line with the symptoms described 
● will provide you with information on where to have your tests performed and may possibly put you in contact with a local health professional 
● will help you interpret the results of your tests

CoVive has a monitoring function which tracks such vital signs as temperature as well as your clinical signs. The app can also notify local healthcare facilities if necessary.

Contact: covive@bionext.lu

The partnerships we have established, particularly with the CHEM and Picken Doheem , allow us to work anywhere in Luxembourg, and to offer you a top local service guaranteeing optimal medical care.

At BioneXt Lab, your health, comfort and quality of life are all equally important to us. In addition to our sampling centres, we offer a home and workplace sample collection service, calling upon a network of nursing and home care specialists.

Download here the list of partner centers

The purpose of CON-VINCE, the COvid-19 National survey for assessing VIral spread by Non-affected CarriErs conducted by the LIH (Luxembourg Institute of Health – www.lih.lu) in cooperation with the University of Luxembourg (www.uni.lu), the LCSB (Luxembourg Centre for Systems Biomedicine-www.lcsb.lu) and the IBBL (Integrated Biobank of Luxembourg – www.ibbl.lu)  is to understand the prevalence of the COVID-19 (SARS-CoV2) infection in the Luxembourgish population so as to assess:

• the psychological impact of the lockdown, and 
• the spread of the virus and the immune status (presence of antibodies) of citizens 

so as to define an exit strategy and a gradual lifting of the lockdown. 

As a partner in this study, the BioneXt LAB makes it human and technical resources available to test the participants who have been selected at the national level by the TNS-ILRES  institute (www.tns-ilres.com) and to conduct analyses. 

Have you been selected for this survey and received a questionnaire to complete with a voucher for the samples to be taken indicating the date and time of your appointment? 

1. You can go to the head office of the BioneXt LAB to undergo the procedure for your samples. 
2. You can call the Pickendoheem mobile service for a sampling at home if you are unable to travel. 

"MyLAB" allows you to access your test results easily and intuitively at any time from your computer, tablet or smartphone. You can also find the nearest sample collection centres and make an appointment for a blood test at a location of your choice with Picken Doheem, find a doctor by speciality or a health centre and make an appointment with Doctena.

Discover all the features of myLAB on www.bionext.lu/santemobile and download the application on

Are you anxious about taking a blood test?

What you may not know is that this anxiety can have a negative impact on your blood workflow.

There is now a simple and effective way to manage your anxiety.

Our medical solution for self-management of anxiety combines validated therapeutic approaches and Virtual Reality. This technique, which is increasingly used in hospitals, reduces the level of anxiety by up to 82%.

Device available by appointment at 8002 40 40.

Spermology is used to study male fertility. In men, the key examination is the spermogram, which evaluates the number and quality of spermatozoa in order to determine if medically assisted reproduction (MAR) should be considered. The BioneXt Lab Laboratory also provides semen preparations for intra-conjugal intrauterine insemination.

Trisomy is a genetic anomaly that is characterized by the presence of an extra chromosome in the cells of a fetus. The trisomy most frequently encountered in humans is trisomy 21, followed by trisomy’s 18 and 13.
The purpose of the NIPT test is to analyze fetal DNA circulating in the maternal blood by means of high throughput sequencing of DNA via NGS (Next Generation Sequencing) technology coupled with a powerful bioinformatics analysis. This method allows a detection rate of trisomy’s higher than 99% without risk for the fetus.

Fast, reliable and safe, the NIPT can detect trisomy’s 13, 18 and 21 with a simple sample of maternal blood and avoids the risk of miscarriage associated with invasive sampling.